CliffBio
small molecule

TRELEGY ELLIPTA

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Loss of exclusivityApril 2031latest FDA-listed patent expiry
CompanyGLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Drug detail

Brand nameTRELEGY ELLIPTA
Active ingredientFLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Strength0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusRX

Listed patents

PatentExpiresType
8746242*PEDApril 2031—
12396986November 2030product
9750726November 2030product
11090294November 2030use U-3202
8746242October 2030product
8534281*PEDSeptember 2030—
8534281March 2030product
7488827December 2027substance, product

More from GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRELEGY ELLIPTA patent cliff — loss of exclusivity April 2031 | CliffBio